- CMS published the premium totals for Medicare on June 21, 2026.
- Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
Medicare negotiates volume discounts on drugs, while lobbying efforts block government cost-trimming.
1 report, 1 independent
Updated Jul 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medicare negotiates volume discounts on drugs, while lobbying efforts block government cost-trimming.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The pharmaceutical industry is pushing a narrative against the 340B drug pricing program.Sub-event
Lobbying efforts prevented government cost-trimming during Medicare drug negotiations.1 source
Keep exploring
The entities involved
-
Big Pharma
artist
Nothing else this week.
-
Medicare
US federal health insurance
Related events
- CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.
- AARP advocated for Medicare to negotiate drug prices in Washington, D.C.
- Administration proposes a rule to manage Medicare drug costs, reported by the Associated Press.
- Government negotiates cost caps for Medicare patients.
- Tariffs are introducing uncertainty into the drug market structure.